References
- Bayraktar S, Arun B. 2017. BRCA mutation genetic testing implications in the United States. The Breast 31:224–232.
- Chen S, Parmigiani G. 2007. Meta-analysis of BRCA1 and BRCA2 penetrance. Journal of Clinical Oncology 25:1329–1333.
- Cho KR, Shih I-M. 2009. Ovarian cancer. Annual Review of Pathology 4:287–313.
- Colombo N, Huang G, Scambia G, Chalas E, Pignata S, Fiorica J, et al. 2018. Evaluation of a streamlined oncologist-led BRCA mutation testing and counseling model for patients with ovarian cancer. Journal of Clinical Oncology 36:1300–1307.
- Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, et al. 2016. Genetic/familial high-risk assessment: breast and ovarian, version 2.2015. Journal of the National Comprehensive Cancer Network 14:153–162.
- Evans D, Lalloo F, Wallace A, Rahman N. 2005. Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. Journal of Medical Genetics 42:e39–e39.
- Karakasis K, Burnier JV, Bowering V, Oza AM, Lheureux S. 2016. Ovarian cancer and BRCA1/2 testing: opportunities to improve clinical care and disease prevention. Frontiers in Oncology 6:119.
- Lancaster JM, Powell CB, Chen L-m, Richardson DL, Committee SCP. 2015. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecologic Oncology 136:3–7.
- NICE. 2013. Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer; [cited 2018 Nov 2]. Available from: https://www.nice.org.uk/guidance/cg164
- NICE. 2016. Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy; [cited 2016 Jul 26]. Available from: https://www.nice.org.uk/guidance/ta381
- NICE. 2019. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy; [cited 2020 Jun17]. Available from: https://www.nice.org.uk/guidance/ta598/chapter/3-Committee-discussion
- Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, et al. 2013. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 24:751–765.
- Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, et al. 2015. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 313:1347–1361.
- Cancer Research. 2016. Ovarian cancer statistics; [cited 2019 Nov 20]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer/incidence
- Walsh T, Casadei S, Lee MK, Pennil CC, Nord AS, Thornton AM, et al. 2011. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America 108:18032–18037.
- WCISU. 2018. Cancer incidence in Wales, 2001–2017; [cited 2020 Jun 16]. Available from: http://www.wcisu.wales.nhs.uk/cancer-incidence-in-wales.